#1 Clinical Trials Search in Europe

Bi 685509

Avenciguat, also known as BI 685509, is an investigational drug being studied in clinical trials for various conditions, including diabetic kidney disease, liver cirrhosis with portal hypertension, and systemic sclerosis. These trials aim to evaluate the safety, tolerability, and efficacy of Avenciguat in treating these complex medical conditions.

Table of Contents

What is BI 685509?

BI 685509, also known as Avenciguat, is a new drug being developed to treat various medical conditions[1]. It is currently undergoing clinical trials to evaluate its safety and effectiveness in treating different diseases. Researchers are studying how the body processes this medication and how it might benefit patients with specific health issues.

Medical Conditions Treated

BI 685509 is being investigated for several medical conditions, including:

  • Portal Hypertension: This is a condition where there is high blood pressure in the main blood vessel (portal vein) that carries blood from the intestines to the liver. BI 685509 is being studied to see if it can help reduce this pressure in patients with liver cirrhosis[3].
  • Systemic Sclerosis (Scleroderma): This is a rare autoimmune disease that causes hardening and tightening of the skin and connective tissues. BI 685509 is being tested to see if it can improve lung function and other symptoms in people with this condition[4].
  • Diabetic Kidney Disease: This is a complication of diabetes that affects the kidneys. Researchers are investigating whether BI 685509 can improve kidney function in patients with this condition[10].

How BI 685509 Works

While the exact mechanism of action is not fully explained in the provided information, BI 685509 appears to have effects on blood vessels and potentially on organ function. In portal hypertension, for example, it may help to reduce the pressure in blood vessels leading to the liver. In systemic sclerosis, it might improve blood flow and reduce fibrosis (scarring) in various organs, particularly the lungs[4].

Clinical Trials

BI 685509 is currently being studied in several clinical trials:

  • Some trials are testing the safety and how the body processes the drug in healthy volunteers[1].
  • Other studies are investigating its effects in patients with specific conditions, such as liver cirrhosis with portal hypertension[3], systemic sclerosis[4], and diabetic kidney disease[10].
  • Researchers are also looking at how food and other medications might affect how BI 685509 works in the body[5].

Administration and Dosage

BI 685509 is typically administered as tablets that are taken orally (by mouth). The dosage and frequency of administration may vary depending on the condition being treated and the specific clinical trial:

  • In some studies, it is taken twice daily[3].
  • In others, it may be taken three times a day[4].
  • The exact dosage is still being determined through clinical trials.

Potential Side Effects

As BI 685509 is still in the research phase, all potential side effects may not be known. However, researchers are closely monitoring for any adverse effects during clinical trials. Some areas of focus include:

  • Effects on blood pressure, including the possibility of low blood pressure (hypotension)[3].
  • Any signs of liver or kidney problems.
  • Other general health effects that may occur during treatment.

Ongoing Research

Research on BI 685509 is ongoing, with several clinical trials in different phases. These studies aim to:

  • Determine the most effective and safe dosages for different conditions.
  • Evaluate how well the drug works compared to placebo or existing treatments.
  • Assess long-term safety and effectiveness.
  • Understand how the drug interacts with food and other medications[5].

As research progresses, more information about BI 685509’s effectiveness, safety profile, and potential uses will become available. Patients interested in this medication should discuss with their healthcare providers about the possibility of participating in clinical trials or when the drug might become available for general use.

Aspect Details
Drug Name Avenciguat (BI 685509)
Conditions Studied Diabetic kidney disease, Liver cirrhosis with portal hypertension, Systemic sclerosis
Administration Oral tablets, varying from once daily to three times a day
Primary Objectives Safety, tolerability, pharmacokinetics, efficacy in treating targeted conditions
Key Outcome Measures UACR, HVPG, FVC, mRSS, adverse events
Trial Durations Varying from a few months to over a year
Study Designs Randomized, placebo-controlled, double-blind, parallel group
Patient Populations Adults with specific conditions, healthy volunteers for some studies

FAQ

  • What is Avenciguat (BI 685509)? Avenciguat, also known as BI 685509, is an investigational drug being studied for its potential to treat various medical conditions, including diabetic kidney disease, liver cirrhosis with portal hypertension, and systemic sclerosis.
  • What conditions is Avenciguat being studied for? Avenciguat is being studied in clinical trials for diabetic kidney disease, liver cirrhosis with portal hypertension, and systemic sclerosis (scleroderma).
  • How is Avenciguat administered in clinical trials? In most clinical trials, Avenciguat is administered orally as tablets. The dosing frequency varies depending on the study, ranging from once daily to three times a day.
  • What are the main objectives of the Avenciguat clinical trials? The main objectives of the clinical trials include assessing the safety and tolerability of Avenciguat, evaluating its pharmacokinetics (how the body processes the drug), and measuring its effectiveness in treating the targeted conditions.
  • How long do the Avenciguat clinical trials typically last? The duration of Avenciguat clinical trials varies depending on the study design and objectives. Some trials last for a few months, while others may extend up to a year or more.

Ongoing Clinical Trials on Bi 685509

  • Study on the Effects of BI 685509 for Patients with Liver Cirrhosis and Portal Hypertension After First Decompensation Event

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Austria France Germany Romania Spain

  • Study on BI 685509 for Adults with Systemic Sclerosis to Assess Effects on Lung Function and Symptoms

    Not recruiting

    1
    Investigated drugs:
    Austria Belgium Czechia Denmark Finland France +11

  • Study on BI 685509 and Empagliflozin for Patients with Portal Hypertension in Compensated Cirrhosis

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Denmark France Germany Italy +3

Glossary

  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body, including their mechanisms of action and the relationship between drug concentration and effect.
  • Urine Albumin Creatinine Ratio (UACR): A test that measures the amount of albumin (a protein) in the urine compared to creatinine, used to assess kidney function and detect early signs of kidney damage.
  • Hepatic Venous Pressure Gradient (HVPG): A measurement of the difference in blood pressure between the portal vein and the hepatic vein, used to assess the severity of portal hypertension in liver disease.
  • Modified Rodnan Skin Score (mRSS): A clinical assessment tool used to measure skin thickness in patients with systemic sclerosis, with higher scores indicating more severe skin involvement.
  • Forced Vital Capacity (FVC): The total amount of air exhaled during a forced breath, used to assess lung function in conditions like systemic sclerosis.
  • Systemic Sclerosis: Also known as scleroderma, a rare autoimmune disease characterized by hardening and tightening of the skin and connective tissues, which can affect various organs.
  • Portal Hypertension: Increased blood pressure in the portal venous system, which can occur as a complication of liver cirrhosis.
  • Diabetic Nephropathy: Kidney damage that occurs as a complication of diabetes, often leading to chronic kidney disease if left untreated.

References

  1. https://clinicaltrials.gov/study/NCT05515328
  2. https://clinicaltrials.gov/study/NCT06272058
  3. https://clinicaltrials.gov/study/NCT05161481
  4. https://clinicaltrials.gov/study/NCT05559580
  5. https://clinicaltrials.gov/study/NCT06193811
  6. https://clinicaltrials.gov/study/NCT05282121
  7. https://clinicaltrials.gov/study/NCT06082843
  8. https://clinicaltrials.gov/study/NCT03116893
  9. https://clinicaltrials.gov/study/NCT03116906
  10. https://clinicaltrials.gov/study/NCT04750577